| abstract |
Novel single-domain antibodies and antibody fragments that specifically bind to PD-L1 and compositions containing the antibodies or antibody fragments are provided. In addition, nucleic acids encoding the antibodies or antibody fragments thereof and host cells comprising the same, and related uses are also provided. In addition, therapeutic and diagnostic uses of these antibodies and antibody fragments are also provided. In particular, combination therapy of these antibodies and antibody fragments with other therapies, eg, therapeutic modalities or therapeutic agents, is provided. |